DexCom
6340 Sequence Drive
San Diego
California
92121
United States
Tel: 858-200-0200
Fax: 858-200-0201
Website: http://www.dexcom.com/
Email: info@dexcom.com
325 articles about DexCom
-
Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter
3/5/2024
DexCom, Inc., the global leader in real-time continuous glucose monitoring for people with diabetes, announced that the FDA has cleared Stelo by Dexcom – the first glucose biosensor that doesn’t require a prescription.
-
Dexcom Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call for February 8, 2024 at 4:30 p.m. Eastern Time
1/23/2024
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2023 financial results after market close on Thursday, February 8, 2024.
-
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2023 and Initial 2024 Outlook
1/8/2024
DexCom, Inc. today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2023 to be at least $1.
-
Dexcom to Present at 42nd Annual J.P. Morgan Healthcare Conference
12/19/2023
DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 42nd annual J.P. Morgan Healthcare Conference on January 8, 2024.
-
Dexcom G7, the Smallest, Most Accurate, Easy-to-Use CGM Now Connects to the Tandem t:slim X2 Insulin Pump
12/6/2023
DexCom, Inc. announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in the United States, marking the first AID integration with the Dexcom G7 CGM, the world’s most accurate1,2 CGM system.
-
Next-Generation Dexcom G7 Continuous Glucose Monitoring System Now Available in Canada
10/5/2023
Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that its next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System will be available on October 10, 2023, for Canadians living with all types of diabetes ages two and older, including those who are pregnant.
-
Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD
10/2/2023
DexCom, Inc. announced new clinical study outcomes that further demonstrate the benefits of CGM use and offered more details about its expanding portfolio of automated insulin delivery offerings at the 59th Annual Meeting of the European Association for the Study of Diabetes held Oct. 2-6, 2023 in Hamburg, Germany.
-
Dexcom Schedules Third Quarter 2023 Earnings Release and Conference Call for October 26, 2023 at 4:30 p.m. Eastern Time.
9/29/2023
DexCom, Inc. announced that it plans to release its third quarter 2023 financial results after market close on Thursday, October 26, 2023.
-
Dexcom Announces Upcoming Conference Presentations - August 30, 2023
8/30/2023
DexCom, Inc. announced that management will present an update on the company at the following upcoming investor conferences: Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present on behalf of the company at the 2023 Wells Fargo Healthcare Conference on Wednesday, September 6, 2023 at 3:45pm.
-
Dexcom Canada Achieves Great Place to Work® Certification for Second Consecutive Year
8/15/2023
Dexcom, Inc., a global leader in real-time continuous glucose monitoring, is proud to announce that for the second consecutive year, it has been certified as a Great Place to Work® in Canada for 2023-24.
-
Dexcom Reports Second Quarter 2023 Financial Results
7/27/2023
DexCom, Inc. reported its financial results as of and for the quarter ended June 30, 2023.
-
Dexcom Schedules Second Quarter 2023 Earnings Release and Conference Call for July 27, 2023 at 4:30 p.m. Eastern Time
7/6/2023
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2023 financial results after market close on Thursday, July 27, 2023.
-
Dexcom G7 Receives Health Canada Approval: Next-Generation Continuous Glucose Monitoring System With Unmatched Accuracy Coming to Canadians
7/4/2023
Dexcom, Inc. announced that Health Canada has approved the next-generation Dexcom G7 Continuous Glucose Monitoring System for people with all types of diabetes, ages two years and older.
-
Global Continuous Glucose Monitoring Pioneer Dexcom Reveals New Plans to Bring Sensing Technology to Millions More
6/24/2023
Dexcom, Inc. announced its strategy to bring Dexcom glucose sensing technology to millions more people around the globe and new Dexcom CGM research featured at the 83rd Scientific Sessions of the American Diabetes Association being held June 23-26 in San Diego.
-
Dexcom to Host Investor Day on June 23, 2023
6/8/2023
DexCom, Inc. (NASDAQ:DXCM) today announced that it will host an Investor Day on June 23rd from 2:30 PM until approximately 5:00 PM PST (5:30 PM – 8:00 PM EST).
-
Dexcom Prices Upsized Offering of $1.1 Billion of 0.375% Convertible Senior Notes Due 2028
5/3/2023
DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today the pricing of its offering of $1.1 billion aggregate principal amount of 0.375% Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).
-
Dexcom Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes
5/2/2023
DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today that it intends to offer, subject to market conditions and other factors, $1.0 billion aggregate principal amount of Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).
-
Dexcom Reports First Quarter 2023 Financial Results
4/27/2023
DexCom, Inc. reported its financial results as of and for the quarter ended March 31, 2023.
-
Dexcom Schedules First Quarter 2023 Earnings Release and Conference Call for April 27, 2023 at 4:30 p.m. Eastern Time
4/6/2023
DexCom, Inc. announced that it plans to release its first quarter 2023 financial results after market close on Thursday, April 27, 2023.
-
DexCom Comments on SVB Relationship
3/13/2023
DexCom, Inc. (NASDAQ: DXCM), today issued the following statement in response to speculation following the developments at Silicon Valley Bank, including a recent CNBC article.